Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transplant Recipients Clear all
Completed No phase listed Observational

Studies of Kidney Transplant Outcome

NCT01277770
View directory record Official record
Conditions
Transplant Recipient (Kidney), Steroid-Free Maintenance Immunosuppression, Post-Transplant Infections, Thymoglobulin
Interventions
Steroid-Free Maintenance Immunosuppression, Infection After Kidney Transplantation, Evaluation of the DGF nomogram in Thymoglobulin
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

CNS Study of Patients Switching From Tacrolimus to Envarsus

NCT03270462
View directory record Official record
Conditions
Renal Transplant Patients
Interventions
Envarsus XR
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Jun 25, 2026, 8:17 PM EDT
Terminated No phase listed Observational

MISP 60528 Pneumococcal Vaccination

NCT04845945
View directory record Official record
Conditions
Heart Transplant Infection Prevention
Interventions
PCV15
Biological
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 25, 2026, 8:17 PM EDT
Recruiting No phase listed Observational

Immune Registry for BK in Kidney Transplant Recipients

NCT06538961
View directory record Official record
Conditions
BK Virus Infection, Kidney Transplant; Complications
Interventions
Blood samples: Main Study group, Data Collection, Urine Sample- Main Study group, Urine sample- Sub-study group, Blood sample: Sub-study group
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Deceased Organ Donor Interventions to Protect Kidney Graft Function

NCT02525510
View directory record Official record
Conditions
Brain Death, Organ Donation, Organ Transplant Failure or Rejection, Delayed Graft Function
Interventions
Pump Eligible - Normothermia - Pump Both Kidneys, Pump Eligible - Hypothermia and Pump Right Kidney, Pump Eligible - Hypothermia and Pump Left Kidney, Not Pump Eligible - Normothermia, Not Pump Eligible - Hypothermia
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jun 25, 2026, 8:17 PM EDT
Active, not recruiting No phase listed Observational

Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients

NCT04212143
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
there is no intervention
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
150 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 1 Interventional

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

NCT02083250
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Fludarabine Phosphate, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Vorinostat
Procedure · Biological · Drug + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Jun 25, 2026, 8:17 PM EDT
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jun 25, 2026, 8:17 PM EDT
Terminated No phase listed Observational

Allosure in Simultaneous Pancreas Kidney Transplant

NCT04777617
View directory record Official record
Conditions
Kidney Pancreas Transplant
Interventions
DD-cfDNA
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 1 Interventional Results available

A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.

NCT00377741
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
14 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
5
States / cities
Los Angeles, California • Denver, Colorado • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients

NCT00615966
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Diannexin, Placebo
Drug
Lead sponsor
Alavita Pharmaceuticals Inc
Industry
Eligibility
21 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Baltimore, Maryland • Livingston, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

NCT01329185
View directory record Official record
Conditions
EBV Viremia, CMV Viremia
Interventions
Valganciclovir, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
6 Months and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jun 25, 2026, 8:17 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Performance Comparison of QuantiFERON Monitor in Solid Organ Transplant Recipients

NCT02416414
View directory record Official record
Conditions
Cell-mediated Immune Response
Interventions
QuantiFERON Monitor Assay, Existing methodology
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Jun 25, 2026, 8:17 PM EDT
Terminated No phase listed Observational

Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients

NCT00504218
View directory record Official record
Conditions
Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 24 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 3 Interventional

A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients

NCT00098007
View directory record Official record
Conditions
Heart Transplantation
Interventions
Everolimus (Certican)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

NCT05518487
View directory record Official record
Conditions
COVID-19, Kidney Transplant
Interventions
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jun 25, 2026, 8:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional

The Effects of Music Therapy-Based Stress Reduction on Bone Marrow Transplant Recipients

NCT00032409
View directory record Official record
Conditions
Bone Marrow Transplantation, Stem Cell Transplantation
Interventions
Music therapy-based relaxation/stress reduction
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 4 Interventional

Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants

NCT00001107
View directory record Official record
Conditions
Candidiasis
Interventions
Fluconazole, AmBisome
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jun 25, 2026, 8:17 PM EDT
Terminated Phase 4 Interventional Results available

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

NCT00931255
View directory record Official record
Conditions
Kidney Transplant, Delayed Graft Function
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jun 25, 2026, 8:17 PM EDT
Completed No phase listed Observational

Immune Monitoring in Sensitized Patients at Risk of Rejection

NCT03794817
View directory record Official record
Conditions
Kidney Failure
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Jun 25, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

Bela 8 Week Dosing

NCT02560558
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Belatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Jun 25, 2026, 8:17 PM EDT
Active, not recruiting Phase 2 Interventional

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096
View directory record Official record
Conditions
Delayed Graft Function
Interventions
ARGX-117, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 25, 2026, 8:17 PM EDT